Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis

Published:2020-10 Issue: Volume:347 Page:577317
ISSN:0165-5728
Container-title:Journal of Neuroimmunology
language:en
Short-container-title:Journal of Neuroimmunology

Author:

Tian Xin,Chen Chaoyang,Ma Lingyun,Wei Ran,Li Min,Wang Xiaoqing,Wu Ye,Zhou Ying,Cui Yimin

Funder

Development Center for Medical Science & Technology

National Health Commission of the People's Republic of China

Drug Innovation Major Project

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,Immunology,Immunology and Allergy

Reference44 articles.

1. Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study;Alcala;J. Neurol.,2018

2. Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe;Alcala;J. Neurol.,2019

3. Safety and efficacy of rituximab: experience of a single multiple sclerosis center;Alldredge;Clin. Neuropharmacol.,2018

4. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients;Alping;Ann. Neurol.,2016

5. Clinical predictors of disease progression in multiple sclerosis patients with relapsing onset in a nation-wide cohort;Alroughani;Int. J. Neurosci.,2015

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Real-World Experience of Rituximab: A Panacea in Therapy of Multiple Sclerosis in Low- and Middle-Income Setting;Clinical Neuropharmacology;2024-09-12

2. Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder;Scientific Reports;2024-02-12

3. Efficacy and safety of rituximab in multiple sclerosis: a systematic review and meta-analysis;Acta Neurologica Belgica;2023-07-10

4. Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: Effectiveness and value;Journal of Managed Care & Specialty Pharmacy;2023-07

5. Estrategias de manejo de terapias de alta eficacia para esclerosis múltiple en la práctica clínica;Neurología Argentina;2023-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3